2 completed, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Terminated 1 |
Follow ALS-L1023: new trials by email Literature Review of ALS-L1023 trials Research Report on ALS-L1023
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH Placebo oral tablet, ALS-L1023 1,200mg, ALS-L1023 1,800mg - Nonalcoholic Steatohepatitis | Phase 2 | Completed | AngioLab, Inc. | 60 | 2019-12-04 | 2022-08-11 |
| Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD ALS-L1023, Ranibizumab, Placebo - Age-Related Macular Degeneration | Phase 2 | Completed | AngioLab, Inc. | 126 | 2018-12-07 | 2022-08-11 |
| Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome ALS-L1023, placebo - Abdominal Obesity Metabolic Syndrome | Phase 3 | Terminated | Hanmi Pharmaceutical Company Limited | 200 | 2013-05-01 | 2016-10-11 |
Abdominal obesity metabolic syndrome (1) · Macular Degeneration (1) · Non-alcoholic Fatty Liver Disease (1)
AngioLab, Inc. (2) · Hanmi Pharmaceutical Company Limited (1)
South Korea (3)
Dae Won Jun, Ph. D. (1) · Hye Soon Park, M.D., Ph.D., M.P.H. (1) · SeWoong Kang (1)